June 12th 2025
Zilucoplan (Zilbrysq; UCB) is a once-daily subcutaneous C5 complement inhibitor that has demonstrated long-term treatment benefits in patients who have acetylcholine receptor antibody–positive generalized myasthenia gravis (gMG).
Patients With MG Report Higher Azathioprine Discontinuation vs Other Immunosuppressants